公开(公告)号：US20210284635A1

公开(公告)日：2021-09-16

申请号：US17071311

申请日：2020-10-15

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Nichola Smith ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61P9/06 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20190263803A1

公开(公告)日：2019-08-29

申请号：US16290313

申请日：2019-03-01

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61P9/06 ,  A61K31/675 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4375 ,  C07F9/6561 ,  A61K45/06 ,  A61K31/541

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20250034108A1

公开(公告)日：2025-01-30

申请号：US18764471

申请日：2024-07-05

Applicant: NOVARTIS AG

Inventor： Robert Francis DAY ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Adam FRIEDMAN ,  Tyler HARRISON ,  Jay Francis LARROW ,  Yunshan PENG ,  Nichola SMITH ,  Haihao TANG ,  Yanxiang WU ,  Sandra Marie KING ,  Sii Hong LAU ,  Tajesh PATEL

IPC: C07D401/04 ,  A61K31/41 ,  A61K31/4439 ,  C07D257/04

Abstract: The present disclosure relates to sulfonamide compounds, the use thereof for modulating the sodium channel Nav1.5 and methods of treating or preventing diseases, disorders, or conditions using the same.

公开(公告)号：US20180111932A1

公开(公告)日：2018-04-26

申请号：US15788248

申请日：2017-10-19

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61K31/4375 ,  A61K45/06 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07F9/6561 ,  A61K31/675

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  A61P9/06 ,  C07B2200/13 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.